Tazemetostat, an inhibitor of EZH2 (enhancer of zeste homolog 2), is approved as a treatment for SMARCB1-deficient epithelioid sarcomas (a rare type of cancer), even though it shows limited clinical efficacy9. This evidence concerns the gene SMARCB1 and epithelioid sarcoma.